ESR1 and breast carcinoma: Breast cancer samples investigated for positivity or negativity of ER, HER2 and PR (Figure 2D–F) with the highest expression in the following receptor combinations ER+/HER2− (67.8%), PR+/HER2− (55.5%) and ER+/PR+ (56.8%).